6/28/23, 12:07 AM ALLHAT (CCB) Pathway Feedback Search Clinical Topics Home Studies ALLHAT CCB ALLHAT CCB Disease Hypertension Trial question Is amlodipine superior to chlorthalidone in high-risk patients with hypertension? Study design Multi-center Double blinded RCT Population Characteristics of study participants 47.0% female N = 24303 53.0% male 24303 patients (11451 female, 12852 male) Inclusion criteria: patients 55 years of age with hypertension and at least 1 other coronary heart disease risk factor Key exclusion criteria: history of hospitalized or treated symptomatic HF and/or known LVEF < 35% Interventions N=9048 amlodipine (a dose of 2.5-10 mg/day) N=15255 chlorthalidone (a dose of 12.5-25 mg/day) Primary outcome Rate of fatal coronary heart disease or nonfatal myocardial infarction within 6 years https://web.pathway.md/studies/reclltMKIEpDQcI9V 1/2 6/28/23, 12:07 AM ALLHAT (CCB) Pathway 11.5 % 11.5 11.3 8.6 % 5.8 % 2.9 % No significant difference 0.0 % Amlodipine Chlorthalidone No significant difference in the rate of fatal coronary heart disease or nonfatal myocardial infarction within 6 years (11.3% vs. 11.5%; RR 0.98, 95% CI 0.9 to 1.07) Secondary outcomes No significant difference in the rate of death from all causes within 6 years (16.8% vs. 17.3%; RR 0.96, 96% CI 0.89 to 1.02) No significant difference in the rate of coronary heart disease within 6 years (19.9% vs. 19.9%; RR 1, 95% CI 0.94 to 1.07) No significant difference in the rate of stroke within 6 years (5.4% vs. 5.6%; RR 0.93, 95% CI 0.82 to 1.06) Safety outcomes No significant difference in hospitalization for gastrointestinal bleeding. Conclusion In patients 55 years of age with hypertension and at least 1 other coronary heart disease risk factor, amlodipine was not superior to chlorthalidone with respect to the rate of fatal coronary heart disease or nonfatal myocardial infarction within 6 years. Reference ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002 Dec 18;288(23):2981-97. Open reference URL https://web.pathway.md/studies/reclltMKIEpDQcI9V 2/2